Luis Prieto's research while affiliated with Universidad Católica San Antonio de Murcia and other places

... Thromboembolic events and many cardiovascular diseases are widely treated with anticoagulants, which have great benefit to patients [16] and have many characteristics that can affect patients' daily lives. Ample of studies have been established to study anticoagulant treatment satisfaction and self-efficacy; however, these studies did not correlate the two concepts with each other [8,10,[17][18][19][20][21][22][23][24][25][26][27][28]. Therefore, the purpose of this investigation is to explore the association between treatment satisfaction and self-efficacy in a sample of patients using anticoagulation therapy and determine the influence of sociodemographic and clinical factors on both aspects. ...

... De hecho, salvo alguna contraindicación específica, se recomienda la anticoagulación para reducir el riesgo de presentar complicaciones tromboembólicas en los pacientes con riesgo elevado de presentar ictus 1,7,8 . Sin embargo, a pesar de esta recomendación, un número significativo de pacientes no se encuentran anticoagulados o no están tomando el tratamiento antitrombótico de manera apropiada, sea por un insuficiente control de la anticoagulación en los que están tomando antagonistas de la vitamina K (AVK) o porque los tratados con anticoagulantes orales de acción directa (ACOD) toman dosis inadecuadas para sus características clínicas [9][10][11] . Este tratamiento antitrombótico inapropiado ocurre con más frecuencia en las personas de mayor edad, posiblemente por un excesivo miedo al riesgo de hemorragias asociado al tratamiento anticoagulante en esta población, a pesar del riesgo elevado de ictus [12][13][14] . ...

... La identificación de comorbilidades y otros factores que elevan el riesgo de enfermedad cardiovascular es muy importante para establecer las medidas de salud pública que puedan lograr algún tipo de impacto sobre la presentación de estos trastornos. Los datos de presencia de hipertensión arterial en esta muestra (93,2%) son superiores a los reportados por estudios hechos en España (48,0%), Francia (70,2%) y Argentina (29,5%) en poblaciones con riesgo cardiovascular, pero en todos los casos demuestra la relación que se ha podido establecer entre hipertensión y la coexistencia de dislipidemias (11,(15)(16)(17) . ...

... The high degree of variability of IFNL3, VKORC1 and CYP4F2 identified leads to a high proportion of individuals who will need a therapeutical change of the associated drugs peginterferon-ribavirin and warfarin, respectively. Nevertheless, this fact does not translate into a clinical effect in the Spanish population since in Spain the use of peginterferon has been mostly replaced by direct-acting antiviral agents (DAAs), which achieve better sustained virologic responses in patients [43] and the use of warfarin is scarce [44]. On the contrary, acenocoumarol is the most used anticoagulant in the Spanish population [44] and, although there is no clinical guideline from the CPIC consortium, the DPWG group recommends a reduction of 50% of the initial dose in VKORC1-1639 (rs9923231) AA homozygous patients [9], which in our study represents 40% of the population, highlighting the potential impact in the Spanish clinical setting. ...

... Major scienti c societies advocate these therapeutic options, which consider thromboembolic prevention vital in AF patients, with the goal of improving their prognosis and quality of life [2,7,8]. In part, primary health care (PHC) has a huge speci c weight in anticoagulation treatment, with the percentage of patients identi ed and followed up in our clinics exceeding 70% according to the most recent national data; thus, we cannot evade this obligation [9,10]. Until recently, dicoumarins or vitamin K antagonists (VKA), such as acenocoumarol (Sintrom®) and warfarin (Aldocumar®), were the conventional treatment for oral anticoagulation. ...

... The LERZAMIG study, [84] performed in obese or overweight patients, showed that the antihypertensive efficacy of lercanidipine is independent of body mass index or excessive body fat. At the end of treatment, a "very good response" was rated by 51% of evaluating physicians. ...

... Принципиально важным является то, что препарат эффективен у пациентов с АГ всех групп сердечно-сосу-дистого риска, причем, наибольший эффект наблюдался у больных из группы наиболее высокого риска [34]. ...

... Most of the predictive models described for patients with HF are mainly based on constitutional aspects: (age [10][11][12], gender [12], body mass index [13,14]), clinical data detected through exploration [15,16], biochemical markers [10,17,18], kidney function impairment parameters [10,[19][20][21], hyponatremia [17,22,23], electrocardiographic alterations (QRS prolongation, QRS low voltage, atrial fibrillation) [24], the findings in the cardiac function test as echocardiogram (left ventricular ejection fraction [LVEF] < 45%) [20,25,26], left atrial diameter or right ventricle dysfunction, New York Heart Association functional classification (NYHA) [10,11,18,20,27], alteration of the 6-minute walk test [28] or associated diseases, such as hypertension, chronic obstructive pulmonary disease, diabetes or kidney disease [10-12, 18, 21, 22, 29-31]. ...

... This drug demonstrates superior tolerability compared to other dihydropyridines. Daily clinical use of lercanidipine reveals an overall prevalence of adverse reactions of 6.5%, the majority of which include headaches (2.9%), ankle edema (1.2%), flushing (1.1%), and palpitations (0.6%) [45]. According to V Barrios et al. [46], the occurrence and severity of these side effects are significantly lower for lercanidipine in comparison to amlodipine/nifedipine. ...

... While men more frequently suffer from HF as a consequence of ischemic heart disease (3)(4)(5)(6)(7), women with HF present with more frequent comorbidities such as hypertension, obesity and diabetes Besides, women with HF have higher left ventricular ejection fraction (LVEF) than men (8,9). In fact, in acute decompensated HF, women tend to have preserved left ventricular systolic function almost twice as often as men (3,10). HF management also has several sex-related differences, with women being less frequently studied for their underlying HF-etiology and their LVEF less often assessed than in men. ...